8-K: MacroGenics Study Hold Lifted by FDA

MacroGenics announces the FDA has removed a partial clinical hold on its Phase 2 LINNET study for lorigerlimab in gynecologic cancers, allowing for new patient enrollment.

Summary

• MacroGenics, Inc. announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on its Phase 2 LINNET study.
• The study is evaluating lorigerlimab, an investigational bispecific DART molecule targeting PD-1 and CTLA-4, in patients with gynecologic cancers.
• Previously enrolled participants could continue receiving study drug, and new participants will now be enrolled under a revised protocol.
• The revised protocol includes additional risk-mitigation measures for potential hematologic and cardiac toxicities.
• The company plans to resume enrollment of new participants and expects to provide a mid-year clinical update on the program.
• The LINNET study is evaluating single-agent lorigerlimab in up to approximately 60 eligible study participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC) who have received one or more prior lines of therapy.
• To date, 41 study participants have been dosed in the LINNET study, and over 300 participants have been dosed across all previous lorigerlimab Phase 1 and Phase 2 studies.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the removal of a clinical hold allows for continued study progression and potential future success of the drug candidate.

Positives

• The FDA has removed the partial clinical hold on the Phase 2 LINNET study, allowing for the resumption of new patient enrollment.
• The company is on track to provide a mid-2026 program update.
• Previously enrolled participants in the LINNET study were permitted to continue receiving study drug during the hold.
• The company received a positive and productive interaction with the FDA's Office of Oncologic Diseases.

Negatives

• The partial clinical hold required the implementation of a revised protocol with additional risk-mitigation measures for potential hematologic and cardiac toxicities.
• The study is evaluating a bispecific DART molecule that targets PD-1 and CTLA-4, which are known to have potential toxicities.

Risks

• Potential hematologic and cardiac toxicities associated with lorigerlimab require additional risk-mitigation measures in the revised protocol.
• The forward-looking statements section highlights risks related to the market acceptance, competition, reimbursement, and regulatory actions for product candidates.
• There are uncertainties inherent in the initiation and enrollment of future clinical trials.
• The company faces risks related to the availability of financing to fund internal development.
• The impact of competitive products and the ability to enter into agreements with strategic partners are potential risks.
• Business, economic, or political disruptions due to catastrophes, natural disasters, terrorist attacks, civil unrest, armed conflict, or public health crises could impact operations.
• Costs of litigation and the failure to successfully defend lawsuits and other claims are a risk.

Future Outlook

MacroGenics intends to resume enrollment of new study participants in the LINNET study and remains on track to provide a mid-year clinical update on the program. The company's forward-looking statements indicate expectations regarding future data updates, clinical trial initiations, regulatory processes, and potential milestone payments, though actual results may differ materially.

Management Comments

• "We are grateful for the productive interaction with the reviewers at the FDA's Office of Oncologic Diseases, as well as the diligent efforts of the MacroGenics team to provide a rapid and comprehensive response to the FDA," said Eric Risser, President and Chief Executive Officer of MacroGenics.
• "With the partial clinical hold lifted, we intend to resume enrollment of new study participants in the ongoing LINNET study and we remain on track to provide a mid-year clinical update on the program."

Industry Context

StockSavvy.ai notes that the lifting of a partial clinical hold by the FDA is a significant positive development for MacroGenics, indicating progress in the clinical development of lorigerlimab. This allows the company to move forward with its research in gynecologic cancers, a critical area of unmet need. The focus on bispecific DART molecules targeting PD-1 and CTLA-4 aligns with broader trends in immuno-oncology.

Stakeholder Impact

• Shareholders: Positive impact due to progress in clinical development and potential for future drug approval.
• Patients: Potential benefit from continued access to investigational treatment and future availability of new therapies.
• Employees: Positive impact from continued company operations and research efforts.
• Regulatory Bodies: Indicates a successful resolution of a regulatory concern and ongoing collaboration.

Next Steps

• Resume enrollment of new study participants in the LINNET study.
• Provide a mid-year clinical update on the program.
• Implement revised protocol with additional risk-mitigation measures for potential hematologic and cardiac toxicities.

Key Dates

Recommendation

While the lifting of the clinical hold is a positive step, the company is still in the clinical-stage with ongoing trials and potential risks associated with drug development and regulatory approval. Further data from the LINNET study and other pipeline developments are needed to warrant a stronger recommendation.

Keywords

MacroGenics, lorigerlimab, LINNET study, FDA, clinical hold, gynecologic cancers, PD-1, CTLA-4